Breast cancer+3
RecruitingStudy on the Safety and Effectiveness of Capivasertib and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer After Hormone Treatment
Study on the Safety and Effectiveness of Capivasertib and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer After Hormone Treatment
- Disease:Breast cancerHormone receptor positive breast cancer+2
- Substances:Capivasertib
Belgium- Participants:18–64 years · 65+ years
- Substances:Capivasertib
- Sponsor:WSG Women's Cancer Study Group GmbH











